Project Grant HT94252510426
Award Date
6/1/25
Completion Date
5/31/28
Dollars Obligated
$1.6M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55414, USA
Similar Awards
This federal Project Grant award from the Department of the Army Medical Command (CFDA 12.420 - Military Medical Research and Development) provides $1,348,041.00 to the Regents of the University of Minnesota to develop a RET-specific proteomic assay from circulating tumor cells in lethal prostate cancer. The award began on Mar 1, 2024 and is scheduled for completion by Feb 28, 2027. This research aims to transform health care for military service members and the general public through innovative...
This $1,848,000.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the University of Minnesota's research on "Therapeutic Targeting of Aberrant mRNA Polyadenylation in Lethal Prostate Cancer." The 3-year project, running from July 1, 2025 to June 30, 2028, aims to investigate innovative approaches to preventing, diagnosing, and treating prostate cancer, with a focus on developing new therapeutic...
This federal Project Grant award under the Military Medical Research and Development program (CFDA 12.420), administered by the Defense Health Agency, provides $231,000.00 in funding to the Regents of the University of Minnesota for the development of AI-designed de novo miniproteins coupled with small molecules to initiate immune cell-mediated eradication of PSMA-expressing castration-resistant prostate cancer (CRPC) cells. The award period runs from June 1, 2025 to May 31, 2027, indicating a...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,243,750 Project Grant to the Regents of the University of Minnesota, doing business as the Office of Sponsored Projects Administration, to develop allogeneic, multiplex base-edited, dual-targeted gamma delta CAR-T cell therapies for the treatment of metastatic castration-resistant prostate cancer. This 3-year award, with a project period from Sep 30, 2024 to Sep 29, 2027, will...
The Regents of the University of Minnesota received a three-year, $532,038 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research into estrogen-driven tumorigenesis in invasive lobular carcinoma from July 15, 2022 to July 14, 2025. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military and...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $1,155,000.00 to the Regents of the University of Minnesota for a 4-year project to evaluate prostate cancer patient natural killer cell function across racial backgrounds and address functional disparities with trispecific killer engagers. The research aims to advance scientific understanding and treatment of prostate cancer, a condition particularly...
This $1,539,818.00 Department of the Army Medical Command federal Project Grant award under the Military Medical Research and Development program (CFDA 12.420) will fund research led by the Regents of the University of Minnesota to develop multiplex edited, dual CAR gamma delta T cells targeting pediatric solid tumors. The three-year project, with a performance period from November 15, 2024 to November 14, 2027, seeks to advance innovative cell-based immunotherapies for the treatment of...
The University of Minnesota, through its Office of Sponsored Projects Administration, was awarded a $1,521,386 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to engage the immune system to kill sarcoma through a comparative oncology approach. The 3-year grant, which began on July 15, 2023 and will be completed by July 14, 2026, supports basic, applied, and advanced biomedical research to transform healthcare for service...
The Regents of the University of Minnesota received a $515,187 Project Grant award from the Defense Health Agency to conduct research titled "Leveraging Reactivation of Tissue-Resident Memory T Cells in the Tumor Microenvironment for Oncolytic Virotherapy." The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical...
The University of Minnesota has been awarded a $665,335 Project Grant from the U.S. Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on July 1, 2024, will fund research to investigate "Trapping Inhibitory Signals in Synergy with Cytokine Signaling to Maximize NK Cell Immunotherapy in Ovarian Cancer." The project, set to run through June 30, 2028, aims to develop new immunotherapy approaches for treating...